Selectivity analysis of protein kinase CK2 inhibitors DMAT, TBB and resorufin in cisplatin-induced stress responses

International Journal of Oncology

Volumn 35, Issue 5, 2009, Pages 1151-1157

  Fritz, Gerhard ^a   Issinger, Olaf Georg ^b   Olsen, Birgitte Brinkmann ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cisplatin; CK2; DNA PK; Protein kinase inhibitors; Stress kinases

Indexed keywords

2 DIMETHYLAMINO 4,5,6,7 TETRABROMO 1H BENZIMIDAZOLE; 4,5,6,7 TETRABROMOBENZOTRIAZOLE; CASEIN KINASE II; CISPLATIN; DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; RESORUFIN; UNCLASSIFIED DRUG;

ARTICLE; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; GENOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRESS; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BLOTTING, WESTERN; CASEIN KINASE II; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; ENZYME INHIBITORS; HUMANS; OXAZINES; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; TRIAZOLES;

EID: 70449590043     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000431     Document Type: Article

References (45)

1. Niefind K, Guerra B, Pinna LA, Issinger OG and Schomburg D: Crystal structure of the catalytic subunit of protein kinase CK2 from Zea Mays at 2.1 A resolution. EMBO J 17: 2451-2462, 1998. (Pubitemid 28221181)
2. Niefind K, Guerra B, Ermakowa I and Issinger OG: Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J 20: 5320-5331, 2001. (Pubitemid 32959451)
3. Chantalat L, Leroy D, Filhol O, et al: Crystal structure of the human protein kinase CK2 regulatory subunit reveals its zinc finger mediated dimerization. EMBO J 18: 2930-2940, 1999. (Pubitemid 29255602)
4. Ermakowa I, Boldyreff B, Issinger OG and Niefind K: Crystal structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit. J Mol Biol 330: 925-934, 2003. (Pubitemid 36818891)
5. Raaf J, Brunstein E, Issinger OG and Niefind K: The interaction of CK2alpha and CK2beta, the subunits of protein kinase CK2, requires CK2beta in a preformed conformation and is enthalpically driven. Protein Sci 17: 2180-2186, 2008.
6. Niefind K and Issinger OG: Targeting protein/protein interactions. Screening 1: 18-21, 2008.
7. Niefind K, Pütter M, Guerra B, Issinger OG and Schomburg D: GTP plus water mimic ATP in the active site of protein kinase CK2. Nat Struct Biol 6: 1100-1103, 1999.
8. Ahmed K, Gerber DA and Cochet C: Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 12: 226-230, 2002. (Pubitemid 34327615)
9. Guerra B, Siemer S, Boldyreff B and Issinger OG: Protein kinase CK2: evidence for a protein kinase CK2beta subunit fraction, devoid of the catalytic alpha subunit, in mouse brain and testicles. FEBS Lett 462: 353-357, 1999.
10. Buchou T, Vernet M, Blond O, et al: Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 23: 908-915, 2003. (Pubitemid 36133509)
11. Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O'Brien C and Seldin DC: The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol 28: 131-139, 2008.
12. Xu X, Toselli PA, Russell LD and Seldin DC: Globozoospermia in mice lacking the casein kinase II alpha' catalytic subunit. Nat Genet 23: 118-121, 1999. (Pubitemid 29418801)
13. Litchfield DW: Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369: 1-15, 2003.
14. Bibby AC and Litchfield DW: The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta. Int J Biol Sci 1: 67-79, 2005.
15. Olsen BB and Guerra B: Ability of CK2beta to selectively regulate protein kinases. Mol Cell Biochem 316: 115-126, 2008.
16. Guerra B and Issinger OG: Protein kinase CK2 in human diseases. Curr Med Chem 15: 1875-1886, 2008.
17. Sarno S and Pinna LA: Protein kinase CK2 as a druggable target. Mol Biosyst 4: 889-894, 2008.
18. Pagano MA, Cesaro L, Meggio F and Pinna LA: Protein kinase CK2: a newcomer in the 'druggable kinome'. Biochem Soc Trans 34: 1303-1306, 2006.
19. Sarno S, Salvi M, Battistutta R, Zanotti G and Pinna LA: Features and potentials of ATP-site directed CK2 inhibitors. Biochim Biophys Acta 1754: 263-270, 2005. (Pubitemid 41797707)
20. Nie Z, Perretta C, Erickson P, et al: Structure-based design, synthesis, and study of pyrazolo(1,5-a)(1,3,5)triazine derivatives as potent inhibitors of protein kinase CK2. Bioorg Med Chem Lett 17: 4191-4195, 2007.
21. Nie Z, Perretta C, Erickson P, et al: Structure-based design and synthesis of novel macrocyclic pyrazolo(1,5-a) (1,3,5)triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities. Bioorg Med Chem Lett 18: 619-623, 2008.
22. Persson T, Yde CW, Rasmussen JE, Rasmussen TL, Guerra B, Issinger OG and Nielsen J: Pyrazole carboxamides and carboxylic acids as protein kinase inhibitors in aberrant eukaryotic signal transduction: induction of growth arrest in MCF-7 cancer cells. Org Biomol Chem 5: 3963-3970, 2007. (Pubitemid 350205976)
23. Pagano MA, Andrzejewska M, Ruzzene M, et al: Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem 47: 6239-6247, 2004.
24. Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z and Pinna LA: 2-Dimethylamino-4,5,6,7- tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 321: 1040-1044, 2004.
25. Olsen BB, Rasmussen T, Niefind K, and Issinger OG: Biochemical characterization of CK2alpha and alpha' paralogues and their derived holoenzymes: evidence for the existence of a heterotrimeric CK2alpha' -holoenzyme forming trimeric complexes. Mol Cell Biochem 316: 37-47, 2008.
26. Pagano MA, Bain J, Kazimierczuk Z, et al: The selectivity of inhibitors of protein kinase CK2. An update. Biochem J 415: 353-365, 2008.
27. Sandholt I, Olsen BB, Guerra B and Issinger OG: Resorufin, a lead for a new protein kinase CK2 inhibitor. Anticancer Drugs 20: 238-248, 2009.
28. Zhang J, Yang PL and Gray NS: Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39, 2009.
29. Boldyreff B, Rasmussen T, Jensen HH, Cloutier A, Baudet L, Roby P and Issinger OG: Expression and purification of PI3 kinase alpha and development of an ATP depletion and an alphascreen PI3 kinase activity assay. J Biomol Screen 13: 1035-1040, 2008.
30. Achari Y and Lees-Miller SP: Detection of DNA-dependent protein kinase in extracts from human and rodent cells. In: Methods in Molecular Biology. Stress response: Methods and Protocols. Vol.99. Keyse SM (ed.). Humana Press Inc., pp85-97, 2000.
31. Brozovic A and Osmak M: Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251: 1-16, 2007. (Pubitemid 46589761)
32. Fritz G and Kaina B: Late activation of stress kinases (SAPK/ JNK) by genotoxins requires the DNA repair proteins DNAPKc and CSB. Mol Cell Biol 17: 851-861, 2006. (Pubitemid 43191118)
33. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868, 1998.
34. Sedelnikova OA, Pilch DR, Redon C and Bonner WM: Histone H2AX in DNA damage and repair Cancer Biol Ther 2: 233-235, 2003.
35. Olive PL and Banáth JP: Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom 76: 79-90, 2008.
36. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S and Pommier Y: Gamma H2AX and cancer. Nat Rev Cancer 8: 957-967, 2008.
37. http://dtp.nci.nih.gov/dtpstandard/servlet/doseresponse?search type=NSC&searchlist=12097
38. Knight ZA, Gonzalez B, Feldman ME, et al: A pharmacological map of the PI3-K family defines a role for p110± in insulin signaling. Cell 125: 733-747, 2006.
39. Kastan M and Bartek J: Cell-cycle checkpoints and cancer. Nature 432 316-323, 2004.
40. Spycher C, Miller ES, Townsend K, et al: Constitutive phosphorylation of MDC1 physically links the MRE11-RAD50-NBS1 complex to DNA damage. J Cell Biol 181: 227-240, 2008. (Pubitemid 351574549)
41. Chapman JR and Jackson SP: Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at the sites of DNA damage. EMBO Rep 9: 795-801, 2008.
42. Fritz G and Kaina B: Activation of c-jun N-terminal kinase 1 by UV irradiation is inhibited by wortmannin without affecting c-jun expression. Mol Cell Biol 19: 1768-1774, 1999. (Pubitemid 29098235)
43. Wu L, Luo K, Lou Z and Chen J: MDC1 regulates intra-S-phase checkpoint by targeting NBS1 to DNA double-strand breaks. Proc Natl Acad Sci USA 105: 11200-11206, 2008.
44. Melander F, Bekker-Jensen S, Falck J, Bartek J, Mailand N and Lukas J: Phosphorylation of SDT repeats in the MDC1 N-terminus triggers retention of NBS1 at the DNA damage-modified chromatin. J Cell Biol 181 213-226, 2008. (Pubitemid 351574548)
45. Loizou JL, El-Khamisy SF, Zlatanou A, et al: The protein kinase CK2 facilitates repair of chromosomal DNA singlestrand breaks. Cell 117: 17-28, 2004. (Pubitemid 38469895)